{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T22:05:55Z","timestamp":1794780355674,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["T32 CA082088"],"award-info":[{"award-number":["T32 CA082088"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA260225"],"award-info":[{"award-number":["K12CA260225"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007261","name":"New York Academy of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017556","name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"The Mark Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eururo.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T17:26:12Z","timestamp":1745688372000},"page":"472-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma"],"prefix":"10.1016","volume":"88","author":[{"given":"Carissa E.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Clinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Rammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze Gokturk","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Akbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Basar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson W.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish K.","family":"Tickoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Rose","family":"Brannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene K.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Yuen","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene J.","family":"Pietzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Sarungbam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.04.008_b0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma: divergent differentiation and morphologic subtypes","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.eururo.2025.04.008_b0010","first-page":"150","article-title":"Invasive urothelial carcinoma","volume":"volume 8. ed. 5","author":"Williamson","year":"2022"},{"key":"10.1016\/j.eururo.2025.04.008_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21037\/tau-22-43","article-title":"Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes","volume":"11","author":"Ogbue","year":"2022","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1464-410X.2010.09900.x","article-title":"Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group\u2013directed intergroup study (S8710)","volume":"108","author":"Scosyrev","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.04.008_b0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/JU.0000000000001325","article-title":"Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy","volume":"205","author":"Hajiran","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2012.04.020","article-title":"The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma","volume":"188","author":"Kim","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.urolonc.2012.08.017","article-title":"Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis","volume":"32","author":"Mitra","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0045","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.04.008_b0050","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.31952","article-title":"Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter?","volume":"125","author":"Berg","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.04.008_b0055","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00345-016-1962-8","article-title":"Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer","volume":"35","author":"Sui","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0065","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.ju.0000162085.20043.1f","article-title":"Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience","volume":"174","author":"Quek","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0075","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.20903","article-title":"Small cell carcinoma of the urinary bladder","volume":"103","author":"Choong","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.04.008_b0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clgc.2022.05.005","article-title":"Long-term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy","volume":"20","author":"Teo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.04.008_b0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/JU.0000000000001071","article-title":"Trends in management and outcomes among patients with urothelial carcinoma undergoing radical cystectomy from 1995 to 2015: the Memorial Sloan Kettering experience","volume":"204","author":"Almassi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2025.04.008_b0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.2892","article-title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma","volume":"224","author":"Al-Ahmadie","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2025.04.008_b0105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111859","article-title":"Genomic heterogeneity as a barrier to precision oncology in urothelial cancer","volume":"41","author":"Clinton","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2025.04.008_b0115","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.04.008_b0120","article-title":"Clinical and genomic characterization of bladder carcinomas with glandular phenotype","volume":"6","author":"Almassi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0125","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.04.008_b0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","article-title":"Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile","volume":"4","author":"Hoffman-Censits","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0135","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2025.04.008_b0140","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2025.04.008_b0145","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1038\/s41467-022-34251-3","article-title":"FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation","volume":"13","author":"Warrick","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2025.04.008_b0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","article-title":"Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience","volume":"18","author":"Iyer","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.04.008_b0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00428-020-02787-8","article-title":"Comparative genomic profiling of glandular bladder tumours","volume":"477","author":"Maurer","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2025.04.008_b0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bju.15428","article-title":"Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy","volume":"129","author":"Almassi","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.04.008_b0165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00027","article-title":"Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype","author":"Kardos","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2025.04.008_b0180","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2021.39.15_suppl.4528","article-title":"Study EV-103: update on durability results and long term outcome of enfortumab vedotin\u00a0+\u00a0pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"39","author":"Friedlander","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.04.008_b0185","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II Open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825002106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825002106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:19:42Z","timestamp":1760221182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0302283825002106"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.04.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}